

Sprint Bioscience adds new cancer drug program to portfolio

Sprint Bioscience AB (publ) announces today that the company is broadening its portfolio with a drug development program for the treatment of acute myeloid leukemia (AML). The program targets the decapping scavenger enzyme (DCPS), a target protein that has been validated both in scientific literature and by Sprint Bioscience in collaboration with Associate Professor Julian Walfridsson at Karolinska Institutet.

The initiation of Sprint Bioscience's DCPS program is part of the company's strategy to capitalize on its platform for small-molecule drug discovery to broaden the portfolio in the cancer area and to bring more opportunities for future licensing deals.

The DCPS program focuses on a target protein that degrades a metabolite resulting from the processing of mRNA. Both small-molecule inhibition and genetic knock-down of DCPS affects the differentiation and proliferation of several AML cell lines as well as patient-derived samples. Furthermore, healthy tissue seems to be insensitive to DCPS inhibition, indicating that DCPS inhibitors could offer a safe and effective treatment option for AML patients. Sprint Bioscience has also identified biomarkers to predict response to DCPS inhibition, enabling patient selection and clinical success for patients with unmet therapeutic needs.

"We have identified a target protein that constitutes a very attractive approach for the treatment of AML. We aim to advance the project to a stage where it can be licensed to an international pharmaceutical company, enabling further clinical development and progression towards the market to benefit AML patients in need of new treatment options," said, Johan Emilsson, CEO of Sprint Bioscience.

AML is a severe type of blood cancer. The Global Burden of Disease study estimates that about 140,000 people around the world are diagnosed with AML on a yearly basis. There is an urgent medical need to identify safe and effective therapies to improve treatment outcomes.

Sprint Bioscience's portfolio now consists of six internal drug development programs (five of which are in cancer) and one program that has been licensed to Day One Biopharmaceuticals.

For further information, kindly contact:

Johan Emilsson, CEO, Sprint Bioscience
Tel: +46 (8) 411 44 55
Epost: johan.emilsson@sprintbioscience.com

About Sprint Bioscience AB (publ)

Sprint Bioscience develops small molecule first-in-class drug programs with a focus on oncology. With a fragment-based drug development method, the company develops drug programs in a time- and resource-efficient manner. The programs are out-licensed to global pharmaceutical companies during the pre-clinical phase and the company has successfully entered into several license agreements. The Sprint Bioscience share is listed on the Nasdaq First North Premier Growth Market and trades under the ticker symbol SPRINT. The company is based in Stockholm with operations located in Huddinge. Further information is available on the company's website; www.sprintbioscience.com. Certified Advisor is FNCA Sweden AB, www.fnca.se.

Attachments

[Sprint Bioscience adds new cancer drug program to portfolio](#)